Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $73.37, but opened at $75.22. Korro Bio shares last traded at $73.99, with a volume of 763 shares changing hands.
Wall Street Analysts Forecast Growth
KRRO has been the topic of several research reports. HC Wainwright boosted their price target on Korro Bio from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, March 28th. Piper Sandler restated an "overweight" rating and set a $180.00 price target on shares of Korro Bio in a research report on Wednesday, March 27th. Royal Bank of Canada upped their price objective on Korro Bio from $70.00 to $90.00 and gave the stock an "outperform" rating in a report on Wednesday, March 27th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and set a $120.00 price objective on shares of Korro Bio in a report on Tuesday, March 26th.
Check Out Our Latest Analysis on Korro Bio
Korro Bio Stock Performance
The business has a fifty day moving average price of $63.33. The stock has a market cap of $555.79 million, a PE ratio of -0.73 and a beta of 2.18.
Institutional Investors Weigh In On Korro Bio
Hedge funds have recently bought and sold shares of the company. Atlas Venture Life Science Advisors LLC acquired a new stake in Korro Bio during the fourth quarter worth approximately $53,648,000. Eventide Asset Management LLC bought a new position in Korro Bio in the fourth quarter valued at approximately $26,185,000. 72 Investment Holdings LLC bought a new position in Korro Bio in the fourth quarter valued at approximately $13,269,000. Vanguard Group Inc. bought a new position in Korro Bio in the fourth quarter valued at approximately $12,988,000. Finally, Point72 Asset Management L.P. bought a new position in Korro Bio in the fourth quarter valued at approximately $12,741,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.
Korro Bio Company Profile
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.
Read More
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
